Congratulations! Innobriv's Off-the-Shelf Allogeneic NK Cell Therapy IND Application Accepted by CDE

IBR733 Injection is a globally innovative product independently developed by Imbioray, consisting of a CD33/CLL1 bispecific antibody conjugated with NK cells. Both its product structure and therapeutic approach are internationally pioneering, marking a significant milestone. Results from investigator-initiated clinical trials (IIT) conducted by Imbioray have shown that IBR733 Injection is highly effective and very safe, offering new hope for patients with AML.

Imbioray is dedicated to addressing the unmet clinical needs in the treatment of tumors and immune-related diseases, primarily focusing on the development of cutting-edge NK cell therapeutic drugs and cell engager products globally. Imbioray has internationally innovative tiNK and CAR-raNK cell technology platforms and advanced processes for large-scale, closed-system in vitro cultivation of NK cells. Based on its proprietary platform technologies, Imbioray has developed several off-the-shelf cell therapy products such as IBR854 and IBR733. Multiple investigator-initiated trials (IITs) have been conducted, preliminarily demonstrating safety and efficacy. Currently, the IBR854 cell injection has progressed to Phase I clinical trials, with several other novel drugs for solid tumors and hematologic malignancies gradually advancing.